As a psychiatric mental health nurse practitioner (PMHNP), how do you approach the management of treatment-resistant schizophrenia, particularly in cases where traditional antipsychotic medications and psychosocial interventions have been ineffective?
What are the challenges and opportunities in utilizing biomarkers of inflammation to aid in the early diagnosis and personalized treatment of Alzheimer’s disease, and how can PMHNPs stay current with advancements in this rapidly evolving field?